Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/8883
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes
david sullivan
Rickey Carter
Michael Joyner
Evan Bloch
Kelly Gebo
Daniel Hanley
Jeffrey Henderson
Liise-anne Pirofski
Shmuel Shoham
Jonathon Senefeld
Aaron Tobian
Chad Wiggins
R. Scott Wright
NIgel Paneth
Arturo Casadevall
Acceso Abierto
Atribución-NoComercial-SinDerivadas
https://doi.org/10.1101/2024.05.16.24307505
https://www.medrxiv.org/content/10.1101/2024.05.16.24307505v1
Abstract In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) for the treatment of hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, we used CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data to estimate the number of actual inpatient lives saved by the treatment with CCP in the USA. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15% to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, CCP was estimated to have saved between 16,187 and 66,160 lives. The ideal use of CCP might have saved as many as 215,195 lives while preventing 1,136,880 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA and this experience has important implications for convalescent plasma used in future infectious disease emergencies.
bioRxiv
18-05-2024
Preimpreso
Inglés
Público en general
VIRUS RESPIRATORIOS
Aparece en las colecciones: Materiales de Consulta y Comunicados Técnicos

Cargar archivos: